Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MYC | P01106 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6223538 | 0.86 | KDM4E (0.45) | KDM4EHPGDPLA2G7MCL1KMT2A | |
| SCHEMBL9586899 | 0.81 | ILK (0.43) | KDM4EHPGDKMT2AL3MBTL1LMNA | |
| SCHEMBL984908 | 0.81 | KDM4E (0.63) | KDM4EHPGDPKMATRNPC1 | |
| SCHEMBL13398544 | 0.81 | KDM4E (0.63) | KDM4EKMT2APRKDCATRNPC1 | |
| SCHEMBL9586556 | 0.81 | CYP1A2 (0.45) | KDM4EHPGDKMT2AL3MBTL1NPC1 | |
| SCHEMBL269667 | 0.78 | KDM4E (1.00) | KDM4ELMNA | |
| SCHEMBL20783705 | 0.76 | KDM4E (0.70) | KDM4EPKML3MBTL1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL9586465 | 0.76 | PMP22 (0.58) | KDM4EHPGDKMT2ANPC1LMNA | |
| SCHEMBL15929451 | 0.75 | RAB9A (0.39) | KDM4EPLA2G7NPC1RAB9A | |
| SCHEMBL13398609 | 0.75 | KDM4E (0.55) | KDM4EDHODHLMNAKIF11CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102471314-B | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction | ROTTAPHARM SPA | 2015-05-13 | — | — | CN | disclosed |
| CN-104334544-A | Benzimidazole-proline derivatives | ACTELION PHARMACEUTICALS LTD | 2015-02-04 | — | — | CN | disclosed |
| CN-104220065-A | Substituted prolines/piperidines as orexin receptor antagonists | EOLAS THERAPEUTICS INC | 2014-12-17 | — | — | CN | disclosed |
| US-8367696-B2 | Aza-bridged-ring compound | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367696-B2 | Aza-bridged-ring compound | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| CN-102471314-A | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction | ROTTAPHARM SPA | 2012-05-23 | — | — | CN | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | disclosed |
| EP-2119716-A1 | AZA-BRIDGED-RING COMPOUND | Astellas Pharma Inc. (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | CHRM3, CHRM1, CHRM2 | KDM4E 1245/4885HPGD 886/4885MYC 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.